Actively Recruiting
Evaluating CRB-701 Versus Investigators Choice Therapy in Previously Treated Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma
Led by Corbus Pharmaceuticals Inc. · Updated on 2026-10-08
260
Participants Needed
111
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying CRB-701, a targeted chemotherapy known as an antibody drug conjugate, to see how well it works as a treatment for oropharyngeal throat, tonsil cancer in patients who have already had platinum-based chemotherapy or immunotherapy. The study also aims to learn about the safety of CRB-701 and how it affects participants quality of life, comparing it with standard care medicines commonly used for this cancer. Participants are randomly assigned to receive either CRB-701 at a dose of 3.6 mgkg intravenously every three weeks or one of the investigators choice therapies, which include capecitabine, cetuximab, or docetaxel. They will continue treatment until the cancer is no longer measurable or controlled. Treatment schedules vary by drug but generally follow cycles of 21 days, with imaging scans like CT or MRI every six weeks to assess cancer response. During the study, participants will visit the clinic every three weeks for infusions and undergo scans every six weeks to monitor their cancer. They will also complete questionnaires to assess their health status and quality of life. Researchers will track response rates, overall survival, progression-free survival, adverse events, and treatment modifications over approximately two to three years from randomization to evaluate treatment effects and safety.
CONDITIONS
Brief Title
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Research Team
C
Clinical Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here